Abstract
Development of CDDP analogues in Japan has been concerned with second generation analogues, especially which need no hydration or minimal hydration with mild nausea and vomiting. There are three compounds, those are 254-S, DWA2114R and NK121 which are in clinical studies at present. The following are structures of three compounds in addition to CDDP and CBDCA for comparison. The structures are different in leaving group, carrier group or both.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Majima, H., Pharmacokinetics of new platinum compounds. 26th Japan Society for Cancer therapy in symposium. 1988.
Niitani, H., Development and clinical application of platinum compounds.
28th Japan Society for Cancer Therapy in symposium. 1990.
Terashima, Y., Clinical application of platinum compounds in GYN fields.
28th Japan Society for Cancer therapy in symposium. 1990.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Majima, H. (1991). Clinical Studies with Cisplatin Analogues, 254-S, DWA2114R and NK121. In: Howell, S.B. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0738-7_32
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0738-7_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0740-0
Online ISBN: 978-1-4899-0738-7
eBook Packages: Springer Book Archive